Cassava Sciences Inc
NASDAQ:SAVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cassava Sciences Inc
Cash from Operating Activities
Cassava Sciences Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cassava Sciences Inc
NASDAQ:SAVA
|
Cash from Operating Activities
-$83.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-77%
|
CAGR 10-Years
-26%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$24.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$14.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
21%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$11.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$16.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$16.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
21%
|
CAGR 10-Years
19%
|
|
Cassava Sciences Inc
Glance View
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 24 full-time employees. The company went IPO on 2000-07-14. The firm is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimer's disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer's brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. The company is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimer's disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.
See Also
What is Cassava Sciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-83.8m
USD
Based on the financial report for Sep 30, 2025, Cassava Sciences Inc's Cash from Operating Activities amounts to -83.8m USD.
What is Cassava Sciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-26%
Over the last year, the Cash from Operating Activities growth was -7%. The average annual Cash from Operating Activities growth rates for Cassava Sciences Inc have been -9% over the past three years , -77% over the past five years , and -26% over the past ten years .
